Meson Decay in the Fock–tani Formalism

Silva, Daniel T. da; Silva, M. L. L. da; Hadjimichef, Dimiter; Vasconcellos, C. A. Z.

doi:10.1142/s0218271807010389

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cardinal symptoms of diabetesexcessive thirst (polydipsia) and frequent urination (polyuria)have been recognized as a pathology for thousands of years in many civilizations, though its association with the pancreas would not be suggested until 1788 . Distinct pancreatic cell clusters, now known as islets of Langerhans, were first identified in histological sections by their namesake Paul Langerhans in 1869, and implicated in the pathogenesis of T1D at the turn of the century. , The contemporary understanding for the basis of T1D as a malfunction of glucose-controlling secretions of the islets of Langerhans emerged into view shortly thereafter . In healthy individuals, pancreatic islets precisely regulate blood glucose by dynamically modulating insulin secretion, which induces glucose uptake in skeletal muscle, liver, and fat cells .…”

Section: Introductionmentioning

confidence: 99%

Hydrogels in Emerging Technologies for Type 1 Diabetes

et al. 2020

View full text Add to dashboard Cite

Type 1 diabetes therapies that afford tighter glycemic control in a more manageable and painless manner for patients has remained a central focus of next-generation diabetes therapies. In many of these emerging technologies, namely, self-regulated insulin delivery and cell replacement therapies, hydrogels are employed to mitigate some of the most long-standing challenges. In this Review, we summarize recent developments in the use of hydrogels for both insulin delivery and insulin-producing cell therapies for type 1 diabetes management. We first outline perspectives in glucose sensitive hydrogels for smart insulin delivery, pH sensitive polymeric hydrogels for oral insulin delivery, and other physiochemical signals used to trigger insulin release from hydrogels. We, then, investigate the use of hydrogels in the encapsulation of insulin secreting cells with a special emphasis on hydrogels designed to mitigate the foreign body response, provide a suitable extracellular microenvironment, and improve mass transfer through oxygen supplementation and vascularization. Evaluations of limitations and promising directions for future research are also considered. Continuing interdisciplinary and collaborative research efforts will be required to produce hydrogels with instructive biochemical microenvironments necessary to address the enduring challenges of emerging type 1 diabetes therapies.

show abstract